Approach

Right from the Start®

The NeuClone Right from the Start® framework underpins our ability to deliver biosimilars with two critical properties: quality excellence and price competitiveness.

 

Producing biosimilars of the highest quality at an affordable price is critical to clinical and commercial success in both developed and rest-of-world (RoW) markets. Our Right from the Start® processes and technologies ensure these outcomes through three key elements:

Approach

Right from the Start®

The NeuClone Right from the Start® framework underpins our ability to deliver biosimilars with two critical properties: quality excellence and price competitiveness.

 

Producing biosimilars of the highest quality at an affordable price is critical to clinical and commercial success in both developed and rest-of-world (RoW) markets. Our Right from the Start® processes and technologies ensure these outcomes through three key elements:

Right Sequence

Early focus on the primary structure (amino acid sequence) of originator products through proprietary processes – including peptide mass fingerprinting, intact mass and X-ray crystallography – ensures the right sequence, from the beginning of development.

Right Approach

NeuClone’s Biosimilarity by Design™ approach is based on QbD principles, to test and confirm biosimilarity from the start. We also use world-leading internal and independent external analytics capabilities for every stage of biosimilar development.

Right Price

Our technologies and Right from the Start® framework allow us to produce biosimilars of high quality, while also enhancing productivity and reducing manufacturing costs downstream (see NeuMAX®). The Serum Institute of India complements our framework by providing expertise in large scale manufacturing at the lowest possible cost. Together, we will deliver the highest quality drugs at the most affordable price.

Learn more about what we do

Download NeuClone Brochure

 

Ellipse2_background-01